JP2018522070A - 白内障の処置用組成物 - Google Patents

白内障の処置用組成物 Download PDF

Info

Publication number
JP2018522070A
JP2018522070A JP2018525507A JP2018525507A JP2018522070A JP 2018522070 A JP2018522070 A JP 2018522070A JP 2018525507 A JP2018525507 A JP 2018525507A JP 2018525507 A JP2018525507 A JP 2018525507A JP 2018522070 A JP2018522070 A JP 2018522070A
Authority
JP
Japan
Prior art keywords
composition
cholestene
steroid
cholesten
diol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018525507A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522070A5 (enExample
Inventor
サム・エル・グエン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Catacore Inc
Original Assignee
Catacore Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catacore Inc filed Critical Catacore Inc
Publication of JP2018522070A publication Critical patent/JP2018522070A/ja
Publication of JP2018522070A5 publication Critical patent/JP2018522070A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018525507A 2015-07-27 2016-07-27 白内障の処置用組成物 Pending JP2018522070A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562197477P 2015-07-27 2015-07-27
US62/197,477 2015-07-27
US201562202518P 2015-08-07 2015-08-07
US62/202,518 2015-08-07
US201562252120P 2015-11-06 2015-11-06
US62/252,120 2015-11-06
US201662295267P 2016-02-15 2016-02-15
US62/295,267 2016-02-15
PCT/US2016/044337 WO2017019808A1 (en) 2015-07-27 2016-07-27 Compositions for the treatment of cataracts

Publications (2)

Publication Number Publication Date
JP2018522070A true JP2018522070A (ja) 2018-08-09
JP2018522070A5 JP2018522070A5 (enExample) 2019-06-20

Family

ID=56616065

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018525507A Pending JP2018522070A (ja) 2015-07-27 2016-07-27 白内障の処置用組成物

Country Status (7)

Country Link
US (2) US10398709B2 (enExample)
EP (1) EP3328389A1 (enExample)
JP (1) JP2018522070A (enExample)
CN (1) CN108472303A (enExample)
AU (1) AU2016298951B2 (enExample)
CA (1) CA2993196A1 (enExample)
WO (1) WO2017019808A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024529735A (ja) * 2021-08-18 2024-08-08 コアンチョウ オキュサン オフサルミック バイオテクノロジー カンパニー リミテッド ステロイド化合物の、飛蚊症を予防及び／又は治療する薬物の調製における応用
JP2024530058A (ja) * 2021-08-06 2024-08-14 フードビカ ソシエダ アノニマ ド キャピタル バリアブル 視覚障害を治療するための眼科用組成物

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
EP3086793B1 (en) 2013-12-24 2022-05-11 Virginia Commonwealth University Use of oxygenated cholesterol sulfates (ocs) for the treatment of kidney dysfunction
CN108350021A (zh) * 2015-09-08 2018-07-31 视点医疗公司 用于治疗眼科疾病的化合物和制剂
KR102593667B1 (ko) 2016-08-02 2023-10-24 버지니아 커먼웰스 유니버시티 5-콜레스텐-3, 25-디올, 3-술페이트 (25hc3s) 또는 이의 약학적으로 허용 가능한 염, 및 적어도 하나의 시클릭 올리고당을 포함하는 조성물
CA3078680A1 (en) * 2017-11-17 2019-05-23 Mahmood Piraee Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders
WO2020003051A1 (en) * 2018-06-27 2020-01-02 Cellix Bio Private Limited Ophthalmic compositions and methods for the treatment of eye disorders
JP2022529363A (ja) * 2019-04-19 2022-06-21 バック・インスティテュート・フォー・リサーチ・オン・エイジング Ｃｒｙａｂ凝集阻害剤である２５－ヒドロキシコレステロール（２５ｈｃ）は新規の老化細胞除去剤である
JP7784525B2 (ja) * 2021-08-18 2025-12-11 コアンチョウ オキュサン オフサルミック バイオテクノロジー カンパニー リミテッド 薬物組成物、その調製方法及び応用
CN115737654B (zh) * 2021-09-03 2025-11-21 成都瑞沐生物医药科技有限公司 一种滴眼给药预防和/或治疗白内障的眼用制剂
EP4467144A4 (en) 2022-01-21 2026-01-21 Senju Usa Inc AQUEOUS LIQUID FORMULATION
AU2023411014A1 (en) * 2022-12-23 2025-08-07 Durect Corporation 25-hydroxy-cholest-5-en-3-sulfate choline, formulations thereof and methods for preparing, and medical uses of same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511713A (ja) * 2001-12-07 2005-04-28 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 加齢性黄斑変性についての処置
WO2014015024A2 (en) * 2012-07-17 2014-01-23 Regents Of The University Of Michigan Non-surgical method of treatment for cataract
WO2015085121A1 (en) * 2013-12-05 2015-06-11 University Of Miami Compositions and methods for reducing intraocular pressure

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798053A (en) 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US4192827A (en) 1974-06-27 1980-03-11 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers
US4136250A (en) 1977-07-20 1979-01-23 Ciba-Geigy Corporation Polysiloxane hydrogels
US4548990A (en) 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US20020132758A1 (en) 2001-01-18 2002-09-19 Shell John W. Method for identifying compounds to treat medical pathologies associated with molecular crystallization
EP2890363A1 (en) 2012-08-31 2015-07-08 Bausch & Lomb Incorporated Ophthalmic compositions with omega-3 fatty acids
WO2016029197A1 (en) 2014-08-22 2016-02-25 Kang Zhang Compositions and methods to treat and/or prevent vision disorders of the lens of the eye
CA2958868A1 (en) * 2014-08-22 2016-02-25 Guangzhou Kangrui Biological Pharmaceutical Technology Co., Ltd. Compositions and methods to treat vision disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511713A (ja) * 2001-12-07 2005-04-28 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 加齢性黄斑変性についての処置
WO2014015024A2 (en) * 2012-07-17 2014-01-23 Regents Of The University Of Michigan Non-surgical method of treatment for cataract
WO2015085121A1 (en) * 2013-12-05 2015-06-11 University Of Miami Compositions and methods for reducing intraocular pressure

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Eye drops could clear up cataracts using newly identified chemical", SCIENCEDAILY, JPN6020013067, 5 November 2015 (2015-11-05), ISSN: 0004248406 *
CENEDELLA RJ: "Cholesterol and cataracts", SURVEY OF OPHTHALMOLOGY, vol. 40, no. 4, JPN6020013071, 1996, pages 320 - 337, ISSN: 0004248408 *
MORI, M. ET AL: "Lanosterol synthase mutations cause cholesterol deficiency-associated cataracts in the Shumiya catar", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 116, no. 2, JPN6020013069, 2006, pages 395 - 404, ISSN: 0004248407 *
REN, S. ET AL: "Identification of novel regulatory cholesterol metabolite, 5-cholesten, 3-beta,25-diol, disultate", PLOS ONE, vol. Vol. 9, Issue 7, JPN6020013073, 2014, pages 103621, ISSN: 0004248409 *
ZHAO, L. ET AL.: "Lanosterol reverses protein aggregation in cataracts", NATURE, vol. 523, JPN6020013065, 30 July 2015 (2015-07-30), pages 607 - 611, ISSN: 0004379417 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024530058A (ja) * 2021-08-06 2024-08-14 フードビカ ソシエダ アノニマ ド キャピタル バリアブル 視覚障害を治療するための眼科用組成物
JP2024529735A (ja) * 2021-08-18 2024-08-08 コアンチョウ オキュサン オフサルミック バイオテクノロジー カンパニー リミテッド ステロイド化合物の、飛蚊症を予防及び／又は治療する薬物の調製における応用
JP7784526B2 (ja) 2021-08-18 2025-12-11 コアンチョウ オキュサン オフサルミック バイオテクノロジー カンパニー リミテッド ステロイド化合物の、飛蚊症を予防及び／又は治療する薬物の調製における応用

Also Published As

Publication number Publication date
CN108472303A (zh) 2018-08-31
EP3328389A1 (en) 2018-06-06
AU2016298951B2 (en) 2019-07-04
AU2016298951A1 (en) 2018-02-22
WO2017019808A1 (en) 2017-02-02
US20200016176A1 (en) 2020-01-16
CA2993196A1 (en) 2017-02-02
US10398709B2 (en) 2019-09-03
US20170027961A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
JP2018522070A (ja) 白内障の処置用組成物
JP7368661B2 (ja) 医薬組成物
CN102811610B (zh) 无刺激性眼科聚维酮碘组合物
TW200400055A (en) Ophthalmic formulation with novel gum composition
US20070287749A1 (en) Bromfenac ophthalmic formulations and methods of use
US20130165419A1 (en) Combination anti-inflammatory ophthalmic compositions
PT2403488E (pt) Veículo oftálmico de libertação controlada
JP2013535485A (ja) 薬物の持続送達のためのコラーゲン系インプラント
JP2011513229A (ja) 補助剤としての眼科用ｎｓａｉｄ
CN107613985A (zh) 含有糖皮质激素的纳米微粒的水性悬浮液剂
TW200803890A (en) Compositions and methods for effecting controlled posterior vitreous detachment
US10864219B2 (en) Compositions and methods for ophthalmic and/or other applications
US11219596B2 (en) Compositions and methods for ophthalmic and/or other applications
EP3265103B1 (en) Compositions comprising an aldosterone antagonist for use in treating dry eyes
WO2014160579A1 (en) Combination anti-inflammatory ophthalmic compositions
CN104721145A (zh) 一种布佐林胺纳米粒眼用制剂及其制备方法
CN104721130B (zh) 一种布林佐胺包合物眼用制剂及其制备方法
TWI896143B (zh) 一種有效延緩及治療近視的藥物組合物
HK40109101A (zh) 一种有效延缓及治疗近视的药物组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190517

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200407

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201104